Longitudinal trends in hiv-1 subtypes and drug resistance in children from argentina over a 15-year period (2006-2021)
-
Natalia J. López [1] ; Solange Arazi-Caillaud [2] ; Rosa M. Bologna [2] ; Andrea M. Mangano [1] ; Cristina P. Aulicino [1]
-
[1] Laboratorio de Biología Celular y Retrovirus (BCYR). Hospital de Pediatría “Prof. Dr. Juan P. Garrahan”, Buenos Aires, Argentina
-
[2] Epidemiology Service, Hospital de Pediatría “Prof. Dr. Juan P. Garrahan”, Buenos Aires, Argentina
-
- Localización: Revista de investigación clínica, ISSN 0034-8376, ISSN-e 2564-8896, Vol. 76, Nº. 1, 2024, págs. 29-36
- Idioma: inglés
- Enlaces
-
Resumen
Human immunodeficiency virus (HIV) drug resistance is a major cause of treatment failure in children and adolescents infected with the virus. Objectives: The objectives of the study are to investigate HIV drug resistance (HIVDR) in patients who attended a referral care center in Argentina over a 15-year period and to compare mutational patterns between HIV-1 pol sequences characterized as B or BF recombinants. Methods: Individual resistance-associated mutations (RAMs) (to protease and reverse transcriptase inhibitors) were identified according to IAS-USA guidelines in 374 HIV-1-infected children and adolescents. HIV-1 subtype was characterized by phylogenetic and recombination analysis using MEGA5.1 and Simplot. Poisson linear regression was used to model the dynamics of the RAMs over time. Results: The prevalence of RAMs to protease inhibitors (R2 = 0.52, p = 0.0012) and nucleoside reverse transcriptase inhibitors (R2 = 0.30, p = 0.0225) decreased over time. HIVDR to non-nucleoside reverse transcriptase inhibitors remained moderate to high, ranging between 33% and 76%. BF recombinants showed a higher frequency of thymidine analog mutation 1 RAMs profile and I54V mutation. Conclusion: In Argentina, HIVDR observed in children and adolescents has decreased over the past 15 years, regardless of the viral subtype. (REV INVEST CLIN. 2024;76(1):29-36)
